Companies 10x Genomics

10x Genomics

Pleasanton

Total Offices: 4

1,518 Total Employees

Year Founded: 2012

View Website

10x Genomics Company Growth, Stability & Outlook

Updated on September 08, 2026

This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about 10x Genomics and has not been reviewed or approved by 10x Genomics.

What's the stability & growth outlook for 10x Genomics?

Strengths in category leadership, IP position, and active platform expansion are accompanied by flat underlying revenue, instrument softness, pricing pressure from lower‑cost alternatives, and continued losses. Together, these dynamics suggest a resilient but tested leader whose near‑term stability hinges on consumables pull‑through, competitive responses to new entrants, and an eventual recovery in instrument demand and research funding.

Key Insight for Candidates

Defining pattern: Recurring consumables growth props up stability while instrument sales swing with NIH‑linked budgets. Expect lumpy revenue, focus on converting a huge installed base and launching assays that drive pull‑through; success is less about boxes sold, more about sustained usage.

Evidence in Action

Quarterly Sequential Guidance Discipline — Q4 2025 guidance of $154–$158M, following Q3 2025 revenue of $149M, codifies a quarterly guidance cadence targeting ~5% sequential growth. Employees align execution to near‑term milestones, focusing on close‑rate discipline, pipeline hygiene, and converting installed‑base demand to stabilize results.
Consumables‑Led Resilience Playbook — Spatial consumables +19% YoY in 2025, >7,000 cumulative instruments, and >20% growth in single‑cell reactions anchor a consumables‑first model. Employees prioritize assay adoption, pull‑through, and customer success over new hardware pushes, strengthening recurring revenue durability and usage‑centric goals.

Positive Themes About 10x Genomics

Strong Market Position & Advantage: 10x is widely regarded as the leader in single‑cell and a co‑leader in spatial biology, with Chromium, Visium and Xenium as reference platforms in many labs. Legal wins and injunctions in spatial further reinforce competitive positioning.
Product Line Growth: Ongoing chemistry and platform updates (GEM‑X, Visium HD, Xenium Protein/RNA multiomics) and launches like next‑gen Chromium Flex indicate continued expansion of content and capabilities. The planned acquisition of Scale Biosciences aims to broaden single‑cell workflows and support medium‑term growth.
Investor Backing & Capital Strength: The company maintains a sizable cash and securities balance alongside a large recurring consumables base. Management is prioritizing cash and costs while guiding quarter‑to‑quarter to navigate a softer funding environment.

Considerations About 10x Genomics

Stagnant Revenue: Core revenue was flat to slightly down in 2025 excluding one‑time items, following a modest decline in 2024. Instrument sales declined materially, weighing on overall growth despite consumables strength.
Weak Market Position & Pricing Challenges: Pricing headwinds and lower‑priced, instrument‑light alternatives are gaining traction. Illumina’s entry via the Fluent BioSciences acquisition increases pressure in single‑cell prep kits.
Declining Profitability: The company remains unprofitable with ongoing losses despite operating discipline improvements. Gross margin pressure and funding uncertainty have delayed a clean return to profitability.

NEW

What does AI tell candidates about your employer brand?

Get your free AI reputation report today.

See AI Report

These insights are generated using AI and may not reflect internal data or verified company information. They are intended solely for general informational purposes and should not be considered a definitive assessment of the company’s reputation. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.